ESSA Pharma Inc. Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition

Reuters

2025/09/10

<a href="https://laohu8.com/S/EPIX">ESSA Pharma Inc.</a> Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition

ESSA Pharma Inc. has announced the adjournment of its special meeting, initially scheduled for September 10, 2025, to September 29, 2025. This decision was made to allow more time for discussions regarding possible revised financial terms of its transaction with XenoTherapeutics, Inc. Under the terms of this transaction, XenoTherapeutics, a non-profit biotechnology company, is set to acquire all issued and outstanding common shares of ESSA Pharma. The company aims to use this additional time to further deliberate on the transaction's terms, including its estimated cash forecast and upfront cash available for distribution to shareholders. The special meeting will be held online via a live interactive webcast.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via CNW (Ref. ID: C0153) on September 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566672256"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566672256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566672256?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566672256","market":"fut","top_or_hot":-1,"title":"ESSA Pharma Inc. Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ESSA Pharma Inc. has announced the adjournment of its special meeting, initially scheduled for September 10, 2025, to September 29, 2025. This decision was made to allow more time for discussions regarding possible revised financial terms of its transaction with XenoTherapeutics, Inc. Under the terms of this transaction, XenoTherapeutics, a non-profit biotechnology company, is set to acquire all issued and outstanding common shares of ESSA Pharma. The company aims to use this additional time to further deliberate on the transaction's terms, including its estimated cash forecast and upfront cash available for distribution to shareholders. The special meeting will be held online via a live interactive webcast.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via CNW (Ref. ID: C0153) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSA Pharma Inc. Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSA Pharma Inc. Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ESSA Pharma Inc. has announced the adjournment of its special meeting, initially scheduled for September 10, 2025, to September 29, 2025. This decision was made to allow more time for discussions regarding possible revised financial terms of its transaction with XenoTherapeutics, Inc. Under the terms of this transaction, XenoTherapeutics, a non-profit biotechnology company, is set to acquire all issued and outstanding common shares of ESSA Pharma. The company aims to use this additional time to further deliberate on the transaction's terms, including its estimated cash forecast and upfront cash available for distribution to shareholders. The special meeting will be held online via a live interactive webcast.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via CNW (Ref. ID: C0153) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPIX","symbol_name":"ESSA Pharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDLbG3HTl:1","article_id":"2566672256","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566672256","pubTimestamp":1757498445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ESSA Pharma Inc. has announced the adjournment of its special meeting, initially scheduled for September 10, 2025, to September 29, 2025. This decision was made to allow more time for discussions regarding possible revised financial terms of its transaction with XenoTherapeutics, Inc. Under the terms of this transaction, XenoTherapeutics, a non-profit biotechnology company, is set to acquire all issued and outstanding common shares of ESSA Pharma. The company aims to use this additional time to further deliberate on the transaction's terms, including its estimated cash forecast and upfront cash available for distribution to shareholders. The special meeting will be held online via a live interactive webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPIX":"ESSA Pharma Inc.","BK4139":"生物科技"},"translate_title":"ESSA Pharma Inc.推迟特别会议以最终确定XenoTherapeutics收购的修订条款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPIX":0.9},"content_text":"ESSA Pharma Inc. Postpones Special Meeting to Finalize Revised Terms of XenoTherapeutics Acquisition\n    \n\n        ESSA Pharma Inc. has announced the adjournment of its special meeting, initially scheduled for September 10, 2025, to September 29, 2025. This decision was made to allow more time for discussions regarding possible revised financial terms of its transaction with XenoTherapeutics, Inc. Under the terms of this transaction, XenoTherapeutics, a non-profit biotechnology company, is set to acquire all issued and outstanding common shares of ESSA Pharma. The company aims to use this additional time to further deliberate on the transaction's terms, including its estimated cash forecast and upfront cash available for distribution to shareholders. The special meeting will be held online via a live interactive webcast.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via CNW (Ref. ID: C0153) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}